RANOLAZINE (ranolazine) by Piramal Pharma is cytochrome p450 3a inhibitors [moa]. Approved for chronic angina. First approved in 2019.
Drug data last refreshed 18h ago
Cytochrome P450 3A Inhibitors
Anti-anginal
Safety and Efficacy of Ranolazine for the Treatment of Amyotrophic Lateral Sclerosis
A TSHRN1201 Sub-study-To Evaluate the Effects of add-on Ranolazine on Exercise Tolerance and Angina Frequency
Effect of Ranolazine on Activity Level in Patients With Angina After FFR Based Deferred Intervention (REPTAR)
Effects of Ranolazine on Coronary Microvascular Dysfunction in Patients With Hypertrophic Cardiomyopathy
Effectiveness of Ranolazine on Reducing Chest Pain in Patients With Blockage But no Stents
Worked on RANOLAZINE at Piramal Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.